We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sensus Healthcare, Inc. (SRTS) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Sensus Healthcare, Inc. (SRTS - Free Report) standing at $6.42, reflecting a -0.47% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw a decrease of 0.06%.
The the stock of company has risen by 30.04% in the past month, leading the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96%.
The investment community will be paying close attention to the earnings performance of Sensus Healthcare, Inc. in its upcoming release. It is anticipated that the company will report an EPS of $0.03, marking a 250% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $7 million, up 54.53% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.30 per share and a revenue of $34.93 million, indicating changes of +900% and +43.13%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Sensus Healthcare, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 3.45% upward. Sensus Healthcare, Inc. is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, Sensus Healthcare, Inc. is currently trading at a Forward P/E ratio of 21.5. This valuation marks a discount compared to its industry's average Forward P/E of 25.31.
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 40% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sensus Healthcare, Inc. (SRTS) Dips More Than Broader Market: What You Should Know
The most recent trading session ended with Sensus Healthcare, Inc. (SRTS - Free Report) standing at $6.42, reflecting a -0.47% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw a decrease of 0.06%.
The the stock of company has risen by 30.04% in the past month, leading the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96%.
The investment community will be paying close attention to the earnings performance of Sensus Healthcare, Inc. in its upcoming release. It is anticipated that the company will report an EPS of $0.03, marking a 250% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $7 million, up 54.53% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.30 per share and a revenue of $34.93 million, indicating changes of +900% and +43.13%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Sensus Healthcare, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 3.45% upward. Sensus Healthcare, Inc. is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, Sensus Healthcare, Inc. is currently trading at a Forward P/E ratio of 21.5. This valuation marks a discount compared to its industry's average Forward P/E of 25.31.
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 40% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.